EcoR1 Capital LLC Buys New Holdings in Replimune Group, Inc. $REPL

Key Points

• EcoR1 Capital acquired 1 million Replimune shares worth approximately $7.65 million, representing a 1.21% stake and 0.3% of its portfolio. Institutional investors collectively own 92.53% of the company.
• Analyst sentiment remains mixed, with a consensus rating of “Hold” and an average price target of $8.86; recent targets range from $4 to $16.
• Replimune opened at $8.63 and recently reported a quarterly loss of $0.76 per share, missing estimates of $0.66, while analysts expect a full-year loss of $2.44 per share.

EcoR1 Capital LLC purchased a new position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,000,000 shares of the company's stock, valued at approximately $7,650,000. Replimune Group accounts for approximately 0.3% of EcoR1 Capital LLC's investment portfolio, making the stock its 20th largest position. EcoR1 Capital LLC owned 1.21% of Replimune Group as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Balyasny Asset Management L.P. boosted its stake in shares of Replimune Group by 507.4% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company's stock worth $11,012,000 after acquiring an additional 2,195,448 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in Replimune Group during the 4th quarter valued at $17,568,000. Commodore Capital LP bought a new position in Replimune Group during the fourth quarter worth $13,851,000. JPMorgan Chase & Co. increased its holdings in shares of Replimune Group by 2,333.6% in the fourth quarter. JPMorgan Chase & Co. now owns 925,173 shares of the company's stock valued at $8,993,000 after purchasing an additional 887,157 shares during the last quarter. Finally, Toronto Dominion Bank raised its position in shares of Replimune Group by 62.5% in the fourth quarter. Toronto Dominion Bank now owns 2,229,527 shares of the company's stock valued at $21,671,000 after purchasing an additional 857,475 shares during the period. Institutional investors and hedge funds own 92.53% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently commented on REPL shares. Piper Sandler downgraded shares of Replimune Group from an "overweight" rating to a "neutral" rating and set a $4.00 target price for the company. in a report on Friday, April 10th. Cantor Fitzgerald downgraded shares of Replimune Group from an "overweight" rating to a "hold" rating in a research report on Monday, April 13th. BMO Capital Markets upgraded Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 price objective for the company in a report on Tuesday, June 30th. Weiss Ratings raised Replimune Group from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, July 20th. Finally, Wedbush increased their target price on Replimune Group from $6.00 to $9.00 and gave the stock a "neutral" rating in a research note on Tuesday, June 30th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, Replimune Group currently has an average rating of "Hold" and a consensus target price of $8.86.

Replimune Group Stock Performance

NASDAQ REPL opened at $8.63 on Tuesday. The firm has a 50-day moving average price of $9.34 and a two-hundred day moving average price of $7.42. Replimune Group, Inc. has a 12-month low of $1.50 and a 12-month high of $12.50. The company has a market capitalization of $724.40 million, a P/E ratio of -2.55 and a beta of 0.86. The company has a quick ratio of 4.79, a current ratio of 4.79 and a debt-to-equity ratio of 0.63.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). Analysts anticipate that Replimune Group, Inc. will post -2.44 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the sale, the insider directly owned 180,962 shares of the company's stock, valued at approximately $1,672,088.88. This represents a 6.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by company insiders.

Replimune Group Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.